We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-17.79%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.33B
AUM Growth
-$491M
Cap. Flow
-$49.3M
Cap. Flow %
-3.7%
Top 10 Hldgs %
64.77%
Holding
54
New
6
Increased
6
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$18.2M
2
PLRX icon
Pliant Therapeutics
PLRX
+$18.2M
3
GHRS icon
GH Research
GHRS
+$15.8M
4
CRGX
CARGO Therapeutics
CRGX
+$14.7M
5
BBIO icon
BridgeBio Pharma
BBIO
+$13.5M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$20.2M
2
PCVX icon
Vaxcyte
PCVX
+$20M
3
ACLX
Arcellx
ACLX
+$16.9M
4
AVBP icon
ArriVent BioPharma
AVBP
+$15.6M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YMAB
51
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-425,000
Closed -$3.33M
AVBP icon
52
ArriVent BioPharma
AVBP
$1.44B
– –
-585,462
Closed -$15.6M
ARTV
53
Artiva Biotherapeutics
ARTV
$551M
– –
-103,633
Closed -$1.04M
SEPN
54
Septerna Inc
SEPN
$1.75B
– –
-560,000
Closed -$12.8M
1 2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Cormorant Asset Management held 54 positions worth $1.33B, down 27% from $1.82B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Cormorant Asset Management withdrew a net $49.3M in Q1 2025, closing 10 positions and reducing 13 holdings. Its most notable exit was ArriVent BioPharma, an estimated $15.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Pliant Therapeutics worth $4.05M.

  • Cormorant Asset Management's largest Q1 2025 buy was Pliant Therapeutics: 3,000,000 shares worth $4.05M.
  • Cormorant Asset Management added most to Edgewise Therapeutics in Q1 2025, an estimated $18.2M increase.
  • Cormorant Asset Management's biggest Q1 2025 reduction was Avidity Biosciences, cutting an estimated $20.2M.
  • Cormorant Asset Management fully exited ArriVent BioPharma in Q1 2025, selling an estimated $15.6M.
  • Cormorant Asset Management's ten largest holdings make up 65% of its $1.33B portfolio in Q1 2025.
  • Cormorant Asset Management opened 6 new positions and closed 10 in Q1 2025.
  • Cormorant Asset Management's portfolio value fell 27% quarter-over-quarter to $1.33B.

Based on Cormorant Asset Management's 13F filing for Q1 2025, filed 15 May 2025.